Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures

NCT01142193 is registered in ClinicalTrials.gov with Upsher-Smith Laboratories as lead sponsor.

NCT NCT01142193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01142193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures
Lead sponsor
Upsher-Smith Laboratories
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2010
Completion date
January 31, 2013
Enrollment
249 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy